Chemomab Therapeutics Ltd. CMMB
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | -- | -- | 4.83% | -39.61% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | -20.95% | -30.70% | |
| Operating Income | -- | -- | 20.95% | 30.70% | |
| Income Before Tax | -- | -- | 21.43% | 30.77% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | 21.14% | 30.70% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | 21.14% | 30.70% | |
| EBIT | -- | -- | 20.95% | 30.70% | |
| EBITDA | -- | -- | 21.00% | 30.74% | |
| EPS Basic | -- | -- | 47.94% | 52.76% | |
| Normalized Basic EPS | -- | -- | -- | 58.00% | |
| EPS Diluted | -- | -- | 47.94% | 52.76% | |
| Normalized Diluted EPS | -- | -- | -- | 58.00% | |
| Average Basic Shares Outstanding | -- | -- | 54.41% | 46.63% | |
| Average Diluted Shares Outstanding | -- | -- | 54.47% | 46.74% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |